Although Anp and Bnp were not attenuated with LNA-antimiR-34a treatment in moderate and severe TAC groups, there was a trend for decreased β-MHC in TAC moderate mice treated with LNA-antimiR-34a, but not in TAC severe mice treated with LNA-antimiR-34a (Figure 4B). The gene discussed is NPPB; the disease is persistent truncus arteriosus.